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Abstract
Aims To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes targeting different
at-risk population subgroups with a lifestyle intervention of varying intensity.
Methods An individual patient simulation model was constructed to simulate the development of diabetes in a
representative sample of adults without diabetes from the UK population. The model incorporates trajectories for
HbA1c, 2-h glucose, fasting plasma glucose, BMI, systolic blood pressure, total cholesterol and HDL cholesterol. Patients
can be diagnosed with diabetes, cardiovascular disease, microvascular complications of diabetes, cancer, osteoarthritis
and depression, or can die. The model collects costs and utilities over a lifetime horizon. The perspective is the UK
National Health Service and personal social services. We used the model to evaluate the population-wide impact of
targeting a lifestyle intervention of varying intensity to six population subgroups defined as high risk for diabetes.
Results The intervention produces 0.0003 to 0.0009 incremental quality-adjusted life years and saves up to £1.04 per
person in the general population, depending upon the subgroup targeted. Cost-effectiveness increases with intervention
intensity. The most cost-effective options are to target individuals with HbA1c > 42 mmol/mol (6%) or with a high
Finnish Diabetes Risk (FINDRISC) probability score (> 0.1).
Conclusion The model indicates that diabetes prevention interventions are likely to be cost-effective and may be cost-
saving over a lifetime. In the model, the criteria for selecting at-risk individuals differentially impact upon diabetes and
cardiovascular disease outcomes, and on the timing of benefits. These findings have implications for deciding who should
be targeted for diabetes prevention interventions.
Diabet. Med. 34, 632–640 (2017)
Introduction
In the United Kingdom (UK), there are 3.5 million people
with diabetes [1]. The prevalence of diabetes is increasing
with growing levels of obesity and an aging population.
Lifestyle interventions targeted at those individuals known to
be at higher risk of Type 2 diabetes have been shown to be
effective in reducing its incidence [2]. Many factors influence
an individual’s risk of Type 2 diabetes including obesity, age,
physical activity and a family history of the disease. People
from certain communities and population groups are at
higher risk, including people of South Asian, African
Caribbean, Black African and Chinese descent, and those
from lower socio-economic groups. Public health guidelines
recommend lifestyle interventions for individuals and com-
munities at high risk of diabetes [3,4], and a national
diabetes prevention programme is currently under develop-
ment in England [5].
Interventions targeting alternative at-risk groups are con-
sidered cost-effective based on economic evaluations [3,4,6].
However, because of differences in the model structures
used, it has not been possible to compare their relative cost-
effectiveness. A recent review of economic evaluations for
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diabetes prevention interventions identified that to compare
prevention interventions within a common framework it is
necessary to incorporate multiple risk factors for diabetes,
diabetes-related complications and obesity-related comor-
bidity outcomes [7].
This article aims to evaluate whether pragmatic diabetes
prevention programmes of varying intensity have differential
effects when targeted at alternative at-risk groups within the
population through the use of a flexible new economic model.
Methods
The School for Public Health Research diabetes prevention
model
The School for Public Health (SPHR) diabetes model is a
micro-simulation model with a lifetime horizon that was
developed to forecast long-term health outcomes and health-
care costs for the evaluation of diabetes prevention strategies.
The model was developed in accordance with a new
conceptual modelling framework to guide modellers when
constructing complex public health models [8]. Given the
complexity of this model, a detailed description of the
methods and assumptions are provided in Supporting
Information File S1 and parameter values can be found in
Supporting Information File S2.
The model incorporates individual-level trajectories for
BMI, HbA1c, 2-h glucose, fasting plasma glucose, systolic
blood pressure, total cholesterol and HDL cholesterol. The
trajectories are based upon statistical analysis of the White-
hall II cohort [9]. The model was designed to simulate a
representative sample of the UK population, by using
individuals from survey data from the 2011 Health Survey
for England [10]. Individuals aged < 16 years and those with
a prior diagnosis of diabetes were excluded, leaving a
population of 8038 from which individuals were sampled
at random. The characteristics of this population and missing
data imputation methods are described in Supporting
Information File S1. Figure 1 illustrates the sequence of
updating clinical characteristics and clinical events (see
Supporting Information File S1). This sequence was repeated
for every annual cycle of the model.
Detection of diabetes, hypertension and cardiovascular risk
In any model cycle, individuals with one or more general
practitioner (GP) visits may receive an opportunistic diag-
nosis of diabetes, hypertension or statin eligibility. The
Whitehall II trajectory model determines HbA1c, systolic
blood pressure and cholesterol test results. Following diag-
nosis and treatment initiation, the trajectories for these risk
factors are modified. When an individual is diagnosed with
Type 2 diabetes following two consecutive HbA1c tests
> 47.5 mmol/mol (6.5%), the model simulates subsequent
HbA1c test results using the UK Prospective Diabetes Study
(UKPDS) outcomes model [11]. Furthermore, if an individual
is prescribed anti-hypertensive treatment or statins in line
with national guidelines [12,13], their systolic blood pressure
or total cholesterol is reduced in line with changes observed
in randomized controlled trials [14,15] and held constant for
all subsequent cycles. The frequency of GP visits was
estimated from data from the South Yorkshire cohort
adjusted for individual characteristics. Details of the study
population and the method to simulate GP attendance are
described in Supporting Information File S1.
Long-term health outcomes
The model simulates several health outcomes that are related
to BMI and diabetes. Further details of how these conditions
were diagnosed and all other health outcomes are provided
in File S1. The QRISK2 algorithm was used to estimate the
probability of a cardiovascular disease (CVD) event condi-
tional on metabolic data, smoking, ethnicity, deprivation,
diabetes and other covariates included in the equation [16].
CVD events were allocated to either stable angina,
unstable angina, myocardial infarction, transient ischaemic
attack, stroke, death from coronary heart disease or vascular
disease according to probability distributions used in a
previous Health Technology Assessment [17]. This source
was also used to estimate subsequent CVD events if the first
event was not fatal.
The probability of congestive heart failure was estimated
from the Framingham Heart Study congestive heart disease
risk model for men and women [18]. Microvascular events
including renal failure, blindness, foot ulcer and amputation
were simulated using the UKPDS outcomes models [11,19].
Breast and colorectal cancer incidence [20,21] was esti-
mated from analysis of the EPIC-Norfolk cohort. The
What’s new?
• We describe the first study to compare the cost-
effectiveness of a lifestyle intervention to prevent
diabetes across different high-risk population sub-
groups and over different intervention intensities.
• We find that diabetes prevention programmes are cost-
effective over a lifetime horizon, regardless of risk
criteria or intervention intensity.
• Our study estimates that a lifestyle intervention will
have a differential impact on disease outcomes (diabetes
vs. cardiovascular disease) and the time horizon of cost
savings in different high-risk groups.
• These findings should help policymakers decide their
objectives in developing suitable criteria for diabetes
prevention programme content and eligibility.
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association between BMI and cancer was obtained from a
large meta-analysis of prospective observational studies [22].
UK mortality statistics determined the risk of mortality after
breast or colorectal cancer [23]. Osteoarthritis incidence and
association with BMI and HbA1c ≥ 48 mmol/mol (6.5%)
were estimated from analysis of an Italian observational
cohort [24]. The incidence of depression in individuals
without diabetes was obtained from a United States cohort
FIGURE 1 SPHR model schematic. See Supporting Information File S1 for a detailed description of the model schematic and how a hypothetical
patient progresses through the model.
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[25]. The risk of depression was inflated upon diagnosis of
diabetes [25] and stroke [26].
Other cause mortality describes the risk of death from any
cause except CVD and cancer. Mortality rates by age and sex
were extracted from the Office for National Statistics,
excluding deaths due to CVD, breast cancer, colorectal
cancer and diabetes [27]. An increased risk of mortality was
assigned to individuals with diabetes using data from a
published meta-analysis [28].
Estimating costs and quality-adjusted life-years
Costs were estimated from a National Health Service (NHS)
and personal social services perspective in 2014–2015 UK
pounds (£). Costs were assigned to the health outcomes
simulated in the model to estimate an overall cost for each
individual in the model.
At baseline, EQ-5D scores were extracted from the Health
Survey for England dataset to describe an individual’s health-
related quality of life. A utility decrement for age was applied
to the baseline EQ-5D each year [17]. CVD, cancer,
microvascular disease osteoarthritis and depression were
associated with a utility factor decrement which was multi-
plied by the individual’s utility, adjusted for age. Costs and
quality-adjusted life-years (QALYs) were discounted by
1.5% in line with the UK guidelines for public health
interventions [29]. Details of how costs and utilities were
estimated and how they were used in the model are detailed
in Supporting Information File S1.
The high-risk subgroups
We selected six sets of criteria to identify alternative
subgroups of individuals at high risk of diabetes within the
UK general population. The at-risk groups included individ-
uals of South Asian ethnicity, individuals in the lowest
quintile of deprivation (low socio-economic status), individ-
uals with HbA1c > 42 mmol/mol (6%), individuals with
BMI > 35 kg/m2, individuals aged 40–65, and individuals
with a Finnish Diabetes Risk (FINDRISC) probability score
> 0.1 [30]. Summary characteristics for the six groups and
the general population are reported in Table 1. The propor-
tion of individuals meeting each of the criteria is reported in
Table 1. This shows that some subgroups (age 40–65)
describe a much larger proportion of the population than
others (South Asian). To enable fair comparison between the
six scenarios, we assumed that there was a budget constraint
meaning that only 2% of the total adult population could be
enrolled in the intervention, regardless of the size of the
subgroup. This means that in some groups there will be more
under-utilization of the intervention than other.
The intervention
The effectiveness of the intervention was based on a recent
meta-analysis of diabetes prevention programmes promoting
dietary and/or physical activity lifestyle changes [2]. The
review identified mean changes in BMI, HbA1c, systolic
blood pressure and total cholesterol. To make these changes
conditional on baseline values, we estimated the percentage
change over 12 months. The effects of the intervention were
applied in the first year of the model to all enrolled
individuals and were assumed to deteriorate over 5 years
until the individual returned to their natural growth rate for
metabolic risk factors, consistent with previous National
Institute for Health and Care and Excellence (NICE)
evaluations [31].
The meta-analysis of diabetes prevention interventions [2]
reported a gradient of effect on weight change and BMI
according to adherence of the studies to prevention pro-
gramme guidelines. We used this analysis to evaluate trade-
offs between the investment in an intervention against its
Table 1 Summary of subpopulation characteristics
General UK
population
Age 40–65
years
Low
socio-
economic
status
HbA1c >
42 mmol/mol (6%)
Finnish Diabetes
Risk score > 0.1
BMI ≥
35 kg/m2
South
Asian
Total population (%) 100 48 18 15 12 8 4
Male (%) 44 44 44 45 40 34 42
White (%) 90 92 80 92 96 91 0
Low socio-economic
status (%)
18 15 100 16 16 24 37
Age, years (SD) 48.6 (18.4) 54.1 (8.4) 44.7 (8.2) 61.2 (16.0) 66.3 (14.0) 50.0 (16.0) 38.3 (13.6)
BMI, kg/m2 (SD) 27.2 (5.4) 27.9 (5.3) 27.4 (5.9) 28.7 (5.5) 34.21 (4.0) 39.0 (4.0) 26.6 (5.3)
HbA1c, mmol/mol (SD) 38 39 38 44 41 39 32
HbA1c, % (SD) 5.6 (0.5) 5.7 (0.4) 5.6 (0.5) 6.2 (0.1) 5.9 (0.5) 5.7 (0.6) 5.1 (0.5)
Systolic blood pressure,
mmHg (SD)
125 (17.1) 128 (16.5) 125 (17.0) 133 (17.3) 135 (17.0) 128 (16.9) 120 (15.5)
Total cholesterol
mmol/l (SD)
5.4 (1.1) 5.7 (1.0) 5.3 (1.1) 5.8 (1.0) 5.8 (1.0) 5.5 (1.0) 5.2 (1.1)
HDL cholesterol,
mmol/l (SD)
1.5 (0.4) 1.6 (0.5) 1.5 (0.4) 1.5 (0.5) 1.5 (0.4) 1.5 (0.4) 1.4 (0.4)
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intensity (intensity is defined in broad terms of adherence to
guidelines). The default setting for our model was to evaluate
a moderate intensity intervention, which was equivalent to
the mean change in the meta-analysis. As alternative anal-
yses, we examined the cost-effectiveness of low- and high-
intensity interventions. The effectiveness data for these was
based upon an assumption that either four fewer or four
more NICE guidelines were followed during intervention
implementation, given that adherence to NICE guidelines has
been linked to increased weight loss at 12 months [2]. Direct
effects on glycaemia, systolic blood pressure and total
cholesterol were assumed to vary in line with the measured
effects on BMI. An adjustment was made to the metabolic
growth models to avoid double counting of the indirect
effects of BMI on other metabolic risk factors. The costs of
low-, medium- and high-intensity interventions were an
assumption based on intervention costs estimated in NICE
public health guidance PH38 [31], and are presented in
Table 2 together with effectiveness data. An additional cost
of an HbA1c test (£3) was added to the HbA1c group to
account for the additional cost of identifying these patients
assuming approximately seven people would need to be
screened to identify one participant.
Outcomes
We estimated the incremental costs and incremental QALYs
generated by the intervention compared with the do-nothing
control, averaged across the whole adult general population
simulated, rather than just the intervention beneficiaries.
Because the intervention was cost saving some incremental
cost-effectiveness ratios were negative, implying the inter-
vention dominates do nothing. To overcome the problems
with ranking negative incremental cost-effectiveness ratios,
we estimated the overall incremental monetary benefit of the
interventions per person by assuming a willingness to pay (k)
of £20 000 per QALY. Net benefit values above zero are
cost-effective, with higher values being more cost-effective
than lower values.
inc.Net Benefit ¼ kðinc.QALYÞ  ðinc.COSTÞ
The model also allowed us to estimate the incremental
change in diabetes and CVD diagnoses. Outcomes were
collected after up to 15 years and lifetime to estimate the
timings of cost-savings. To investigate parameter uncertainty,
2000 probabilistic sensitivity analyses samples were run for
20 000 randomly selected individuals per run for the high-
intensity intervention targeting all population subgroups
(Supporting Information File S3). Deterministic analysis
using one million individuals was used to obtain results for
all three intervention intensities together with a series of one-
way sensitivity analyses. A full list of sensitivity analyses/
assumptions tested is reported in Supporting Information
File S4.
Results
The deterministic incremental cost-effectiveness results for
the adult general population are reported in Table 3. The
results describe the net benefit, incremental costs and
incremental QALYs averaged across the whole adult popu-
lation. All three intervention intensities increase QALYs and
are cost-effective over the lifetime of the population, com-
pared with doing nothing. High-intensity interventions are
more cost-effective than interventions of moderate- or low-
intensity. Comparisons between subgroups indicate large
variations in lifetime costs, QALYs and net benefits accrued
for different subpopulations. Targeting interventions to
individuals with HbA1c > 42 mmol/mol (6%), individuals
with high FINDRISC probability score (> 0.1) or individuals
with high BMI are the most cost-effective options. Targeting
South Asian individuals is less cost-effective than any other
option. The incremental results for the individuals receiving
the intervention are reported in Supporting Information
File S3.
Figure 2 illustrates the incremental costs at over 15 years
post intervention to describe how the initial intervention
investment is reduced over time due to cost savings. Interven-
tions for individuals identified by FINDRISC > 0.1 or
HbA1c > 42 mmol/mol (6%) have the smallest costs over
15 years. Low socio-economic status and South Asian groups
take longer to recover costs and are not cost-saving over a
lifetime. There are important differences between the sub-
groups in how health benefits are distributed in terms of
disease events. Interventions in adults aged 40–65, South
Asians and low socio-economic status groups have a similar
reduction in both CVD and diabetes cases. By contrast,
intervening in individuals identifiedwith the FINDRISC > 0.1
or HbA1c > 42 mmol/mol (6%) has a disproportionately
large impact in reducing diabetes diagnosis compared with
other subgroups, but is only marginally more effective in
reducing CVD events.
Results from the probabilistic sensitivity analyses indicate
that the intervention is a likely gain of QALYs in all six
Table 2 Effectiveness of hypothetical prevention intervention
Low
intensity
Medium
intensity
High
intensity
% change in BMI
from baseline
1.3 3.0 4.7
% change in Hba1c
from baseline
1.0 2.2 3.4
% change in systolic
blood pressure
from baseline
1.9 4.3 6.7
% change in total
cholesterol from baseline
1.5 3.4 5.3
Intervention cost (year 1) £43 £100 £157
Follow-up cost per
year (years 2–4)
£26 £60 £94
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subgroups, because the vast majority of probabilistic sensi-
tivity analyses results are located in the southeast or
northeast quadrants of the cost-effectiveness plane (Fig. 3
and Supporting Information File S3). The intervention is also
highly likely to be cost-effective in all subgroups at a threshold
of £20 000/QALY, because probabilistic sensitivity analyses
results are predominantly located to the right of the cost-
effectiveness threshold (dotted line in Fig. 3b). Probabilistic
sensitivity analyses results differ slightly from deterministic
results due to the non-linearity of the model. The cost-
effectiveness acceptability curve indicates that the
HbA1c > 42 mmol/mol (6%) group has a high probability of
cost-effectiveness compared with do nothing (Fig. 3b). Uncer-
tainty around the cost-effectiveness of HbA1c > 42 mmol/mol
(6%) is stable over different willingness to pay thresholds.
Finally, the intervention remains cost-effective in all
population subgroups in all deterministic sensitivity analyses,
and in all cases the HbA1c > 42 mmol/mol (6%) subgroup
remains the most cost-effective. A detailed description of the
results from the sensitivity analysis can be found in
Supporting Information File S4.
Discussion
The analysis has shown that there are potentially substantial
gains in health and cost savings available from diabetes
prevention interventions depending upon the population
Table 3 Incremental simulated outcomes for one million individuals in the general population (adult 16–99 years) over a lifetime perspective
Absolute values Intensity
Targeting strategy (incremental results vs. do nothing)
Do nothing
Adults
aged 40–65
Low
socio-
economic
status
HbA1c >
42 mmol/mol (6%)
Finnish
Diabetes Risk
probability
score > 0.1 BMI > 35 kg/m2 South Asian
A: Incremental net benefit per person (£)
Low 2.80 2.38 9.63 6.29 5.15 1.40
Medium 6.26 4.93 18.93 14.43 10.04 3.96
High 9.72 6.85 27.15 22.44 14.41 5.70
B: Incremental total discounted costs per person (£)
£36 373 Low 0.36 0.76 0.71 0.36 0.84 1.15
Medium 1.58 2.10 0.99 1.04 0.24 2.86
High 2.28 2.77 2.47 1.39 0.24 4.28
C: Incremental total discounted QALYs (per person)
15.548 Low 0.00016 0.00045 0.00030 0.00030 0.00022 0.00013
Medium 0.00039 0.00090 0.00067 0.00067 0.00049 0.00034
High 0.00060 0.000123 0.00123 0.00105 0.00073 0.00050
D: Incremental life years
32.25 million* Low 217 125 687 407 197 108
Medium 580 468 1444 1010 635 372
High 757 577 1816 1621 978 496
E: ICERs (£ per QALY)
Low 2263 4,839 Dominates Dominates Dominates 9027
Medium 4,024 5967 Dominates Dominates Dominates 8381
High 3,808 5759 Dominates Dominates 332 8581
E: Incremental diabetes diagnosis
550 000* Low 19 17 83 63 20 3
Medium 29 32 161 121 38 1
High 38 51 235 176 71 4
F: Incremental cardiovascular disease events
480 000* Low 8 12 16 15 15 2
Medium 30 22 33 40 20 3
High 40 33 50 69 31 14
*Rounded to nearest ten thousand. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
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target or intensity. The new SPHR diabetes prevention model
was developed so that diabetes prevention interventions with
different weight change outcomes can be flexibly specified to
target alternative populations reflecting multiple risk factors
for diabetes and CVD. The analysis highlights that popula-
tion heterogeneity will impact on the cost-effectiveness of
public health interventions. We found that applying the same
intervention in different high-risk groups produces very
different cost-savings and QALY gains, events avoided and
short-term cost-savings.
HbA1c > 42 mmol/mol (6%) and FINDRISC > 0.1 are the
most effective subgroups to target to reduce diabetes
diagnoses, and generate the greatest short- and long-term
cost-savings, although targeting individuals with
HbA1c > 42 mmol/mol (6%) is a much more cost-effective
strategy than targeting FINDRISC > 0.1.
The analysis described here includes several limitations due
to an absence of evidence. In particular, we were not able to
obtain estimates of how intervention effect sizes or interven-
tion costs might vary by subgroup (e.g. due to ease of
recruitment), limiting our ability to make recommendations
about which individuals should be targeted. Further research
directed at subgroup analysis would be extremely useful to
inform this parameter. More generally, the analysis assumed
the reduction in metabolic trajectories following intervention
was proportionate to the individual’s baseline values. How-
ever, in reality, individuals will vary hugely in their response
to intervention, and individuals with very low risk factors
may not experience the same proportionate reduction.
Finally, we base the model on diagnosis of individuals
through HbA1c, but other diagnostic methods (e.g. fasting
plasma glucose) will identify a different subset of individuals
with diabetes [32]. However, we think this is unlikely to
significantly alter the results at the population level.
We used the Framingham heart failure risk score to
describe risk of heart failure in the model. This risk score is
based on old data from the USA and may not be represen-
tative of the UK. However, we do not think that this
limitation has impacted on our overall results. Sensitivity
analyses confirmed that the model was moderately respon-
sive to heart failure incidence, but it did not affect the
conclusions of this article.
Our validation work indicates that the model may over-
estimate diabetes incidence in high impaired glucose regula-
tion populations due to the structure of the model. It is
possible that this may bias the results in favour of the HbA1c
risk group. However, there is a paucity of data on long-term
diabetes incidence for different risk profiles to understand the
extent of this limitation in our model.
The model could be developed in the future to describe
dynamic changes in health behaviours and a broader range of
health outcomes to improve model flexibility and decision-
making. Smoking is included in the model as risk factor for
HbA1c, systolic blood pressure and CVD. We did not include
a dynamic quit rate in the model and did not assume that the
intervention was effective in improving smoking cessation
compared with usual care. Including smoking cessation and
current smoking cessation services would add considerable
complexity to the model. Furthermore, we do not currently
account for non-related healthcare costs that may impact on
the results, particularly where interventions improve survival
[33]. Current NICE guidelines do not require the inclusion of
unrelated healthcare costs, however, we believe that the
model would benefit from inclusion of other health out-
comes, such as dementia.
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Two previous UK-based economic evaluations have found
that lifestyle interventions for diabetes prevention are cost-
effective but not cost-saving in subgroups with either low
socio-economic status or high diabetes risk score and
HbA1c > 42 mmol/mol (6%) [3,4]. The results from the SPHR
model are broadly similar. TheQALYgains for the individuals
receiving the intervention in the HbA1c > 42 mmol/mol (6%)
groupare of similarmagnitude toNICEpublic health guidance
PH38 [4]. We believe that several factors explain the differ-
ences in incremental costs. First, the SPHR model includes a
broader range of health outcomes such as depression,
osteoarthritis, breast and colorectal cancer that were not
included in previous evaluations. Second, the costs of major
events, such as CVDhave increased due to inflation. Third, the
cost of screening individuals for Type 2 diabetes to identify
individuals athighriskdue tohyperglycaemiawasnot included
in this version of the SPHR model.
The main drivers of the model are the impact of the
intervention in reducing diabetes and CVD. A substantial
proportion of incremental costs can be attributed to the
diabetes and CVD-related cost-saving (Supporting Informa-
tion File S3). The deterministic sensitivity analyses highlight
that the model results are most sensitive to changes in the
baseline incidence of these conditions.
In our analysis, we investigated six high-risk groups sepa-
rately, but it is highly likely that combining criteria could
optimize resource allocation to a subpopulation with even
greater gains in health and cost-savings. The SPHRmodel can
be easily modified to evaluate combined treatment criteria, in
addition to a variety of alternative policies for Type 2 diabetes
prevention.UKpolicymakers canuse thismodel todecidewhich
populations they wish to target with lifestyle interventions
according to their overall objectives, whether short- or long-
term gains, equity or efficiency, or preventing CVD or diabetes.
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